Additionally, the findings by Cucè and colleagues (28) and Allavena and colleagues (21) that trabectedin leads to increased tumor cell NKG2D ligand expression and inhibits transcription of cytokines linked to NK-cell dysfunction, such as IL-6, suggests that trabectedin may indirectly activate NK cells in the setting of cancer. This evidence concerns the gene IL6 and neoplasm.